Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | ACP1 | P24666 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814505 | 0.92 | KDM1A (0.46) | KDM1AEHMT2RCOR1HRH3ACP1 | |
| SCHEMBL2816638 | 0.89 | LMNA (0.39) | KDM1AEHMT2RCOR1SIGMAR1 | |
| SCHEMBL537894 | 0.88 | ALDH1A1 (0.38) | KDM1AEHMT2RCOR1SLC2A1TSHR | |
| SCHEMBL2809509 | 0.87 | TYRO3 (0.42) | MKNK1 | |
| SCHEMBL2812174 | 0.86 | LMNA (0.51) | KDM1AEHMT2RCOR1TSHR | |
| SCHEMBL2811945 | 0.85 | ACHE (0.38) | HRH3HRH2HRH1 | |
| SCHEMBL2812003 | 0.85 | KDM1A (0.47) | KDM1AEHMT2RCOR1 | |
| SCHEMBL2812252 | 0.84 | CSNK2A1 (0.36) | — | |
| SCHEMBL2809589 | 0.84 | CSNK2A1 (0.36) | — | |
| SCHEMBL2814891 | 0.84 | HRH2 (0.41) | HRH3ACP1SIGMAR1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414359-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | KDM1A 3360/4885EHMT2 3441/4885RCOR1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.